Commodore Capital’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $68.2M | Buy |
4,875,000
+1,275,000
| +35% | +$17.8M | 4.81% | 8 |
|
|
2025
Q1 | $48.5M | Buy |
3,600,000
+1,200,000
| +50% | +$16.2M | 3.58% | 13 |
|
|
2024
Q4 | $46M | Sell |
2,400,000
-150,124
| -6% | -$2.88M | 3.37% | 12 |
|
|
2024
Q3 | $58M | Buy |
2,550,124
+22,092
| +0.9% | +$503K | 3.63% | 11 |
|
|
2024
Q2 | $32.9M | Buy |
2,528,032
+593,379
| +31% | +$7.72M | 2.25% | 17 |
|
|
2024
Q1 | $33.9M | Buy |
1,934,653
+10,579
| +0.5% | +$185K | 2.27% | 16 |
|
|
2023
Q4 | $41.9M | Sell |
1,924,074
-275,926
| -13% | -$6.01M | 3.66% | 9 |
|
|
2023
Q3 | $33.7M | Hold |
2,200,000
| – | – | 3.94% | 12 |
|
|
2023
Q2 | $52.3M | Buy |
2,200,000
+10,341
| +0.5% | +$246K | 5.88% | 6 |
|
|
2023
Q1 | $55.7M | Buy |
2,189,659
+169,493
| +8% | +$4.31M | 8.48% | 2 |
|
|
2022
Q4 | $59M | Sell |
2,020,166
-676,174
| -25% | -$19.8M | 8.89% | 2 |
|
|
2022
Q3 | $55.3M | Buy |
2,696,340
+1,057,731
| +65% | +$21.7M | 8.89% | 3 |
|
|
2022
Q2 | $19M | Buy |
1,638,609
+687,270
| +72% | +$7.95M | 4.01% | 10 |
|
|
2022
Q1 | $17.6M | Buy |
951,339
+103,656
| +12% | +$1.92M | 3.93% | 10 |
|
|
2021
Q4 | $16.8M | Buy |
847,683
+180,009
| +27% | +$3.56M | 3.88% | 10 |
|
|
2021
Q3 | $11M | Buy |
667,674
+481,269
| +258% | +$7.92M | 2.9% | 14 |
|
|
2021
Q2 | $3.41M | Buy |
186,405
+624
| +0.3% | +$11.4K | 1.19% | 27 |
|
|
2021
Q1 | $3.1M | Buy |
+185,781
| New | +$3.1M | 1.24% | 27 |
|